MetiMedi Co., Ltd.
MetiMedi is developing a first-in-class oral immunotherapeutic small molecule in Phase 2 for solid cancer therapy
5 employees · est. 2016 · Korea South
Odimma Therapeutics
Empowering Personalized Immunotherapy to Treat Cancer
6 employees · est. 2017 · France
MetiMedi Co., Ltd. is the older company (2016 vs 2017).
Side-by-Side Comparison
| Metric | MetiMedi Co., Ltd. | Odimma Therapeutics |
|---|---|---|
| Founded | ||
| Founded | 2016 older | 2017 |
| Headquarters | ||
| Headquarters | Korea South | France |
| Employees | ||
| Employees | 5 | 6 |
| Industry | ||
| Industry | Biotechnology, Health Care | Biotechnology, Health Care, Health and Wellness |
| Funding Stage | ||
| Funding Stage | Not tracked yet | Seed |
| Total Funding | ||
| Total Funding | Not tracked yet | $2.00M |
| Funding Rounds | ||
| Funding Rounds | Not tracked yet | 1 |
| Services | ||
| Services | Not tracked yet | Next-generation precision immunotherapy platform for personalized cancer treatment |
| Target Customers | ||
| Target Customers | Not tracked yet | Patients with hard-to-treat cancers, healthcare providers, research institutions |
| Taxonomy | ||
| Taxonomy | Biopharmaceutical, Immuno-oncology, Cancer Therapy, Solid Tumors, Cell Modulator, Metabolic Reprogramming, Immunotherapy, Phase 2 Clinical Studies, Refractory Metastatic Colorectal Cancer, Cell Metabolism Therapy, Chronic Inflammatory Diseases, Novel Therapy, Innovative Treatment, Immune Activation, Tumor Necroptosis | Immunotherapy, Cancer Treatment, Precision Medicine, Immuno-oncology, Personalized Immunization, Neoantigens, Therapeutic Solutions, Onco-Immunology, Research & Development, DeepTech, Biotech, Clinical Trials, Therapeutic Efficacy, Cancer Immunotherapy, Patient-centric Approach |
| Website | ||
| Website | metimedi.com | odimma-therapeutics.com |
About MetiMedi Co., Ltd.
MetiMedi Co., Ltd., a pioneering bio pharmaceutical company based in South Korea, is carving a niche in the competitive landscape of immuno-oncology with its innovative approach to cancer therapy. Founded in 2016, the company is developing a first-in-class oral immunotherapeutic small molecule know...
About Odimma Therapeutics
Odimma Therapeutics is a French biotech company specializing in active personalized cancer immunotherapy. They aim to improve the efficacy of current therapies by leveraging recent advances in immuno-oncology and harnessing the patient’s own immune system to recognize neoantigens displayed by the tu...
Be first to know when either one moves
Funding rounds, hiring surges, leadership changes and stack switches at MetiMedi Co., Ltd. and Odimma Therapeutics — tracked continuously, sent the day they land.
Funding, hiring, leadership and stack changes at MetiMedi Co., Ltd. and Odimma Therapeutics — by email.
Frequently Asked Questions
Compare MetiMedi Co., Ltd. with someone else
Start typing a company name or domain.